Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.96 USD
+0.06 (6.69%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.94 -0.02 (-2.10%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 21 - 40 ( 326 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Initial Takeaways - Days 1 and 2 of ASGCT 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Announces Restructuring; Fabry and CAR-Treg Programs Advancing; Unveils Neuro Programs; PT Down to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Streamlining Focus on ST-920, TX200 Neuro Epigenetic Programs; Prelim 1Q23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Fabry Program Shines; CAR-Treg Program Advances; Sickle Cell Program in Flux; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM; Ph1/2 STAAR Data Shines at WORLDSymposium; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Latest Data Cuts From Hem-A and Sickle Cell Programs at ASH Demonstrate Progress on Key Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2022: Ph1/2 Updates for SB-525/HemA and SAR445136/ SCD Programs
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Wholly-Owned Fabry, CAR Treg, and Sickle Cell Programs Each on Track With Potential Near-Term Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Ph1/2 Updates for SAR445136/SCD and SB-525/HemA at ASH; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Ph1/2 STAAR Update for ST-920/Fabry at ESGCT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAAR Continues to Shine With Latest Fabry Disease Update at ESGCT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P